Navigation Links
Transcept Pharmaceuticals, Inc. Completes Merger with Novacea, Inc.
Date:2/2/2009

owed by difficulty returning to sleep. Intermezzo(R) Phase 3 clinical trials have been completed and, on September 30, 2008, Transcept submitted a New Drug Application (NDA) for Intermezzo(R) to the U.S. Food and Drug Administration (FDA) which was accepted for filing on December 15, 2008. The FDA has assigned a PDUFA date of July 30, 2009 to the Intermezzo(R) NDA.

For further information, please visit the company's website at: http://www.transcept.com.

Safe Harbor

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Transcept disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the expected timing of potential U.S. Food and Drug Administration (FDA) approval of Intermezzo(R); and the expected timing of commercialization and launch of Intermezzo(R); the estimated net loss of Transcept at December 31, 2008; the pro forma cash, cash equivalents and marketable securities balance of the combined entity as of December 31, 2008; the ability of Transcept to commercialize Intermezzo(R) utilizing the resources of the combined company; expected payments to lenders; expected merger transaction costs; future presentations of management, including planned quarterly conference calls; and the expected benefits of Transcept product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to positive results in clinical trials may not be sufficient to obtain FDA approval; physician or patient reluctance to use Intermezzo(R), if approved; potential alternative therapies; mai
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
2. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
3. Transcept Pharmaceuticals to Present at 19th Annual Piper Jaffray Health Care Conference
4. Transcept Pharmaceuticals to Present at RBC Capital Markets 2007 Healthcare Conference
5. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
6. Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
8. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
9. Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
10. Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Transcept Pharmaceuticals, Inc. to Present at the 20th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Blindness is a reversible ailment these ... of today, despite well-meaning efforts, still have a long way ... for reversing blindness that does not involve any kind of ... alternative medicine takes the “slack” from the mainstream by providing ... harmful surgeries. , Alternative health specialist Kevin Richardson actually ...
(Date:8/1/2014)... Cypress, CA (PRWEB) August 01, 2014 ... to advancing gynecologic endoscopic surgery, is pleased to ... societies, in the United States and Europe, which ... make available to surgeons an endoscopic dry lab ... proficiency of their endoscopic surgery skills. , Endoscopy ...
(Date:8/1/2014)... August 01, 2014 Surftech athletes Jack ... Oahu paddleboard World Championships this past weekend in Hawaii ... 3rd place finisher Zeb Walsh were all on stock ... of the race and athletes this year were treated ... making the course extremely challenging as well as very ...
(Date:8/1/2014)... iFitDress.com, a professional company of women’s dresses ... 2014 silver bridesmaid dresses recently. All of ... latest fashion trends. What’s more, they are now offered ... , iFitDress.com is one of the leading suppliers ... silver bridesmaid gowns, but also many other kinds of ...
(Date:7/31/2014)... Women over the age of 65 face numerous ... greater struggles against poverty and higher rates of asthma ... August issue of Annals of Allergy, Asthma and ... of Allergy, Asthma and Immunology (ACAAI), outlines the challenges ... practical solutions to improve their care. , ...
Breaking Medicine News(10 mins):Health News:The Miracle Cure Review | The Unbeatable Secret to Reversing Any Vision Problem – Vinamy.com 2Health News:AAGL Announces It Has Joined With Other Medical Societies to Encourage Hospitals Teaching Endoscopic Surgery to Establish Simulator Labs for Training 2Health News:Surftech Bark Commander Sweeps Molokai2Oahu Stock Paddleboard Division 2Health News:iFitDress.com: Beautiful Silver Bridesmaid Dresses at Promotional Prices 2Health News:Female baby boomers with asthma? You may need help 2Health News:Female baby boomers with asthma? You may need help 3
... Coalition of patients, practitioners and employers urges ... deployment of interoperable health,information technology, WASHINGTON, ... co-chaired by former Senator John Breaux and ... Eshoo,and Mike Rogers for introducing legislation that ...
... The Pennsylvania,Department of Health today is emphasizing ... for consumers not to eat Banquet brand and,store ... possible,Salmonella contamination., "Federal officials have already shared ... ensure Pennsylvanians are taking the,appropriate measures to protect ...
... Guttmacher,Institute,s latest report on world abortion rates is ... W. Mosher. The,study, just released today, argues that ... developing countries., Accurate numbers are impossible to ... illegal. Says Mosher: "Neither,Guttmacher nor anyone else knows ...
... have discovered a key protein that controls how stem ... move limbs, or smooth muscle cells that support blood ... Proceedings of the National Academy of Sciences (PNAS). ... of muscle types in the human fetus, but also ...
... Ohio, Oct. 10 PartsSource, the nation,s leading,supplier ... &,CEO, A. Ray Dalton has been selected as ... Business" award. This honor is given to,executives who ... new,businesses throughout their professional career. "I am ...
... ... geographically, WILMINGTON, N.C., Oct. 10 ... as senior vice,president of clinical operations for North America and Simon ... Colvin joins PPD from Eli Lilly and Company where he most ...
Cached Medicine News:Health News:Health IT Now! Coalition Applauds Representatives Eshoo and Rogers for Introducing Health IT Legislation 2Health News:Salmonella Outbreak Traced to Banquet and Store Brand Frozen Pot Pies 2Health News:PRI Criticizes Guttmacher Report 2Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 2Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 3Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 4Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 5Health News:PPD Names VPs for North America and Asia 2Health News:PPD Names VPs for North America and Asia 3
(Date:7/31/2014)... -- The Galien Foundation today announced the 2014 nominees ... Awards. The Prix Galien Award is considered ... scientific and clinical research skills necessary to develop innovative ... highest number of nominees since the inception of the ... biomedical products across three categories – biotechnology, pharmaceutical, and ...
(Date:7/31/2014)... Cryoport, Inc. (OTCBB: CYRX) today announced financial results for ... Recent Operating Highlights , Achieved 92% ... period ended June 30, 2014 compared to the prior ... expand Cryoport,s global reach using the ,powered by Cryoport ... an immunotherapy and vaccine development services company, to support ...
(Date:7/31/2014)... , July 31, 2014  Genomic Health, Inc. (Nasdaq: ... a conference call and webcast on Thursday, August 7 at ... financial results.  The call and webcast will follow the release ... Conference Call Details To access the live conference call ... please dial (877) 303-7208 from the United States ...
Breaking Medicine Technology:The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 2The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 3The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 4The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 5Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 2Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 3Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 4Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 5Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 6Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 7Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 8Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 2Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 3Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 4
... Report Issued to Improve Policies Affecting How Human ... At the same time,that medical science is making ... once fatal diseases, a new report finds major,shortcomings ... out and,funded in the U.S. with serious implications ...
... Belgium, April 1 , - Trial Results Expected ... company,focused on vascular diseases, eye diseases and cancer, today ... IIb MIVI III trial in the,United States. This study ... in vitrectomy (MIVI III - Microplasmin for Vitreous,Injection)., ...
Cached Medicine Technology:Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation 2Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation 3Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation 4Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation 5Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation 6Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation 7ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III) 2ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III) 3ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III) 4
ThyroTest TSH is a rapid, qualitative test for hypothyroidism screening in adults....
... A & B Test simplifies rapid ... on the market just got easier ... and influenza B using one simple ... can focus on the results and ...
... Combo with Reference Line Test ... human chorionic gonadotropin (hCG) in ... test kit is used to ... is intended for professional and ...
... Experience the finest surgical-quality loupes ... set the standard for innovative optical ... support. Delivering optimum performance with maximum ... choice for medical professionals worldwide. Make ...
Medicine Products: